Swaminathan Ganesh, Gadepalli Venkat S, Stoilov Ivan, Mecham Robert P, Rao Raj R, Ramamurthi Anand
Department of Biomedical Engineering, Cleveland Clinic, Cleveland, OH, USA.
Department of Biology, University of Akron, Akron, OH, USA.
J Tissue Eng Regen Med. 2017 Mar;11(3):679-693. doi: 10.1002/term.1964. Epub 2014 Nov 6.
Abdominal aortic aneurysms (AAAs) involve slow proteolysis and loss of structural matrix components (collagen and elastin), which lead to wall thinning, weakening and ultimate rupture. At this time, no established non-surgical therapy is available to slow or arrest AAA growth. Inhibiting matrix metalloproteases (MMPs; e.g. MMP2 and -9) overexpressed within AAAs is insufficient to arrest AAA growth, since resident smooth muscle cells (SMCs) are poorly elastogenic and cannot overcome elastolysis to reinstate a healthy elastic matrix. Towards overcoming this limitation, this first study sought to determine the utility of rat bone marrow mesenchymal stem cell (BM-MSC)-derived SMCs to stimulate elastin and elastic matrix synthesis and assembly by aneurysmal SMCs (EaRASMCs). BM-MSCs were successfully differentiated into cells of an SMC lineage (SMLCs). Our study indicates that BM-MSC-derived SMLCs secrete trophic factors, contained in conditioned medium (CM) from their cultures, that, when exposed to EaRASMC cultures in real time, stimulate elastin precursor and matrix deposition and crosslinking by these elastogenically deficient cells, with added benefits in terms of attenuating MMPs, specifically MMP9. The results thus lend support to a proposed cell therapy for AAAs, based on the use of BM-MSC-derived SMLCs. Although we observed no particular improvement in elastic fibre formation, no attenuation of MMP2 activity and increase in amounts of active MMP2 enzyme, we believe that this study justifies follow-up studies to improve upon these outcomes. Future studies will explore the effects of concentrated CM collected from long-term SMLC cultures on EaRASMCs and also investigate the elastogenic output of SMLCs themselves. Copyright © 2014 John Wiley & Sons, Ltd.
腹主动脉瘤(AAA)涉及缓慢的蛋白水解以及结构基质成分(胶原蛋白和弹性蛋白)的丧失,这会导致血管壁变薄、变弱并最终破裂。目前,尚无已确立的非手术疗法可减缓或阻止AAA的生长。抑制AAA内过度表达的基质金属蛋白酶(MMPs,如MMP2和MMP9)不足以阻止AAA的生长,因为驻留的平滑肌细胞(SMCs)弹性生成能力较差,无法克服弹性蛋白分解以恢复健康的弹性基质。为了克服这一限制,本第一项研究旨在确定大鼠骨髓间充质干细胞(BM-MSC)来源的平滑肌细胞刺激动脉瘤性平滑肌细胞(EaRASMCs)合成和组装弹性蛋白及弹性基质的效用。BM-MSCs成功分化为平滑肌细胞系(SMLCs)的细胞。我们的研究表明,BM-MSC来源的SMLCs分泌其培养条件培养基(CM)中所含的营养因子,当实时将这些营养因子暴露于EaRASMC培养物时,可刺激这些弹性生成能力不足的细胞进行弹性蛋白前体和基质的沉积及交联,在减弱MMPs尤其是MMP9方面还有额外益处。因此,这些结果支持了基于使用BM-MSC来源的SMLCs对AAA进行细胞治疗的提议。尽管我们未观察到弹性纤维形成有特别改善,MMP2活性未减弱且活性MMP2酶量未增加,但我们认为本研究为改善这些结果的后续研究提供了依据。未来的研究将探索从长期SMLC培养物中收集的浓缩CM对EaRASMCs的影响,并研究SMLCs自身的弹性生成能力。版权所有© 2014 John Wiley & Sons, Ltd.